Dance-movement Therapy Programme in Fibromyalgia.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02144116|
Recruitment Status : Unknown
Verified October 2016 by Marie Carmen Valenza, Universidad de Granada.
Recruitment status was: Recruiting
First Posted : May 21, 2014
Last Update Posted : October 28, 2016
|Condition or disease||Intervention/treatment||Phase|
|Fibromyalgia||Other: Dance-movement therapy Other: Control group||Not Applicable|
Fibromyalgia is a chronic condition associated with balance problems and pain. It has been previously described that fibromyalgia may affect peripheral and/or central mechanisms of postural control. Balance or postural stability is a very complex task that involves the integration of multiple sensory inputs to execute appropriate neuromuscular activity needed to maintain balance.
Patients with fibromyalgia have also muscle weakness. Muscle strength depends on both the cross-sectional area of the muscle and the neural activity. Range of movement and quality of life have also been reported to be affected.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||48 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Effects of a Dance-movement Therapy Programme in Patients With Fibromyalgia.|
|Study Start Date :||May 2014|
|Estimated Primary Completion Date :||December 2016|
|Estimated Study Completion Date :||January 2017|
Experimental: Experimental group
Patients with fibromyalgia included in a dance-movement therapy programme
Other: Dance-movement therapy
The dance-movement was practised in groups. Dance-movement therapy derived from dance education. The goals of dance-movement therapy included assessing patient needs, communicating emotions, improving self-control, organizing thoughts and actions, developing interpersonal skills, integrating physical and emotional selves, promoting body awareness, and supporting healing.
Active Comparator: Control group
Patients with fibromyalgia who receive a standardized educational information in the form of a leaflet about balance disorders and quality of life in fibromyalgia.
Other: Control group
Standardized educational information in the form of a leaflet about balance disorders and quality of life in fibromyalgia.
- Changes in balance [ Time Frame: Baseline, 8 weeks ]
Balance is going to be assessed with the Mini BalanceEvaluation System Test. This test assesses dynamic balance, with four subscales:anticipatory postural adjustments, reactive postural control, sensory orientation and dynamic gait.
The Mini BESTest is a 14 item test scored on a 3 level ordinal scale. For the Mini BESTest, the original BESTest 4 level (0 - 3) scoring was revised to 3 levels (0 - 2) due to redundancy. Total score = 28 points per test directions. Two items have right and left assessment in which the lower score is used within the total score (directions specify which to use). For research, many studies specify use of both left and right data, thus calculating data based on 32 (vs 28) points
- Changes in quadriceps strength [ Time Frame: Baseline, 8 weeks ]Changes from baseline to postintervention on quadriceps strength. This will be measured using a Jamar dynamometer with a standard protocol allowing three attempts on each side. The maximum value achieved from all six attempts was used in analyses. Kg/cm2.
- Changes in quality of life [ Time Frame: Baseline, 8 weeks ]Quality of life associated with health. This is going to be measure with the EuroQol-5 questionnaire.
- Changes in flexibility of lower limbs [ Time Frame: Baseline, 8 weeks ]Changes from baseline to postintervention measured with neurodynamic tests It is going to be measured with a goniometer.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02144116
|Contact: Marie Carmen Valenza, PhDemail@example.com|
|University of Granada||Recruiting|
|Granada, Spain, 18071|
|Contact: Marie Carmen Valenza, PhD 958242360 firstname.lastname@example.org|
|Principal Investigator: Marie Carmen Valenza, PhD|
|Principal Investigator:||Marie Carmen Valenza, PhD||Universidad de Granada|